Cuproptosis-related gene signature correlates with the tumor immune features and predicts the prognosis of early-stage lung adenocarcinoma patients

Abstract

Background: Although a majority of early-stage lung adenocarcinoma (es-LUAD) patients have a favorable prognosis, there are still some cases with a risk of recurrence and metastasis. Cuproptosis is a new form of death that differs from other programmed cell death. However, no study has been reported for setting a prognostic model of es-LUAD using cuproptosis pattern-related genes.Methods: Using multiple R packages, the data from the GEO database was processed, and es-LUAD patients was classified into two patterns based on cuproptosis-related genes. Key differentially expressed genes (DEGs) in the two patterns were screened to construct a prognostic signature to assess differences in biological processes and immunotherapy responses in es-LUAD. Tumor microenvironment (TME) in es-LUAD was analyzed using algorithms such as TIMER and ssGSEA. Then, a more accurate nomogram was constructed by combining risk scores with clinical factors.Results: Functional enrichment analysis revealed that DEGs in two patterns were correlated with organelle fission, nuclear division, chromosome segregation, and cycle-related pathways. Univariate Cox regression and Lasso-Cox regression analyses identified six prognostic genes: ASPM, CCNB2, CDC45, CHEK1, NCAPG, and SPAG5. Based on the constructed model, we found that the high-risk group patients had higher expression of immune checkpoints (CTLA4, LAG3, PD-L1, TIGIT and TIM3), and a lower abundance of immune cells. Lastly, the nomogram was highly accurate in predicting the 1-, 3-, and 5-year survival status of patients with es-LUAD based on risk scores and clinical factors.Conclusion: The cuproptosis pattern-related signature can serve as a potential marker for clinical decision-making. It has huge potential in the future to guide the frequency of follow-up and adjuvant therapy for es-LUAD patients.

Landscape and the immune patterns of cuproptosis in oral squamous cell carcinoma

“…We identified a cluster strongly associated with cuproptosis and classified it as cuproptosis‐related OSCC. This cluster is actively involved in nuclear division, organelle fission, and chromosome segregation, consistent with previous findings on cuproptosis 21 …”

“…This cluster is actively involved in nuclear division, organelle fission, and chromosome segregation, consistent with previous findings on cuproptosis. 21 We established two patterns based on cuproptosis-related genes that displayed distinct differences in the tumor immune microenvironment. Among the two cuproptosis patterns, the most prognostic DEGs were DSG2, C7, DUSP9, PPARG, STK26, GSTCD, MIPOL1, and RYR2.…”

The neurological and non-neurological roles of the primary microcephaly-associated protein ASPM

“…multiple ASPM mutations (Table 2) in tumors. 2 Meanwhile, high levels of ASPM expression correlate with poor prognosis in various types of cancer (Figure 3B), including bladder cancer (Chen et al, 2019(Chen et al, , 2021 2 https://cancer.sanger.ac.uk/cosmic Gao et al, 2020;Liu et al, 2023), prostate cancer (Xie et al, 2017;Pai et al, 2019;Xu et al, 2019), breast cancer (Shubbar et al, 2013;Tang et al, 2019;Wei et al, 2021;Wang et al, 2022), triple-negative breast cancer , esophageal cancer (ESCA; , hepatocellular carcinoma (Lin et al, 2008;Li and Xu, 2020;Yang et al, 2021;Hu et al, 2022;Qiao et al, 2022;Tan et al, 2022;Hasan et al, 2023;Hossen et al, 2023Hossen et al, ), 10.3389/fnins.2023 Frontiers in Neuroscience 13 frontiersin.org glioblastoma (Visnyei et al, 2011;Qin et al, 2023), epithelial ovarian cancer (Brüning-Richardson et al, 2011;Alsiary et al, 2014;, osteosarcoma (Liu et al, 2021), endometrial carcinoma , malignant pleural mesothelioma (Zhang et al, 2020), cervical squamous cell carcinoma (Wen et al, 2020), lung adenocarcinoma (Feng et al, 2021;Hou et al, 2022;Tang et al, 2022;Yin et al, 2022;, anaplastic thyroid carcinoma (Fang et al, 2023), cutaneous squamous cell carcinoma (Su et al, 2022), human sarcomas …”